AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38902952
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy received locally
Trial: 38902994
Drug: nab-paclitaxel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (150 mg/m2 in D1), oxaliplatin (85 mg/m2 in D1), S-1/leucovorin (35 mg/m2 and 30 mg bid from D1 to D7)
Trial: 38903173
Drug: Concurrent taVNS
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent taVNS
Trial: 38903173
Drug: Sequential taVNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential taVNS
Trial: 38903416
Drug: VR treatment
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR treatment (3D with binaural beats)
Trial: 38903523
Drug: LVRNA012 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVRNA012 mRNA vaccine (100ug)
Trial: 38904126
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation behavioural support sessions based on the 5As algorithm and a 6-week supply of nicotine replacement therapy
Trial: 38904165
Drug: E4/DRSP (estetrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E4/DRSP (estetrol 15 mg)
Trial: 38904646
Drug: NT-proBNP <125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP <125 pg/mL
Trial: 38904646
Drug: NT-proBNP ≥125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≥125 pg/mL
Trial: 38904657
Drug: Subjective reports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective reports of activities of daily living and other types of physical activity
Trial: 38904892
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) with concomitant G-CSF
Trial: 38904899
Drug: Amberen (dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amberen (dietary supplement)
Trial: 38904918
Drug: EVE +
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVE + EXE (10 mg/day + 25 mg/day)
Trial: 38904918
Drug: PBO +
RxNorm normalized name: INV-CIRB#20-18 (PREVENTABLE) ATORVASTATIN 40MG/PBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO + EXE (placebo + 25 mg/day)
Trial: 38905148
Drug: PIEB settings
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIEB settings (PIEBnb = 29.4 minutes, PIEBi = 59.8 minutes, PIEBv = 6.2 mL)
Trial: 38905148
Drug: PCEA (volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (volume 6 mL every 10 minutes)
Trial: 38905212
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for ADHD-I (CADDI)
Trial: 38905476
Drug: Couple-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based care and treatment intervention
Trial: 38905580
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (2 g of capsaicin ointment 0.075%) applied four times a day for 5 days
Trial: 38905580
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching ointment)
Trial: 38905928
Drug: Reversal/replacement agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversal/replacement agent administration during hospitalization (specific agents not detailed).
Trial: 38906178
Drug: Cow milk
RxNorm normalized name: cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow milk antibody concentrations in cord blood
Trial: 38906178
Drug: Cow milk
RxNorm normalized name: cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow milk antibody concentrations longitudinally from birth to 3 years
Trial: 38906210
Drug: Relugolix combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate)
Trial: 38906614
Drug: Insulin-and-pramlintide closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-and-pramlintide closed-loop system with simple meal announcements
Trial: 38906614
Drug: Insulin-and-placebo system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-and-placebo system with carbohydrate counting
Trial: 38907052
Drug: Narrow-diameter tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-diameter tissue level implant in T2DM patients
Trial: 38907052
Drug: Narrow-diameter tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-diameter tissue level implant in normoglycemic patients
Trial: 38907104
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 4 weeks (starting dose 160 mg)
Trial: 38907106
Drug: Phenylephrine (PE)
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine (PE) infusion at 15-20 mikrg/min adjusted until preload was restored (SVV < 12%)
Trial: 38907679
Drug: rhPro-UK 35
RxNorm normalized name: Vital E- Repro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPro-UK 35 mg (15 mg bolus + 20 mg infusion/30 min)
Trial: 38907679
Drug: rt-PA 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA 0.9 mg/kg (10% bolus + 90% infusion/1 h)
Trial: 38907679
Drug: rhPro-UK 35
RxNorm normalized name: Vital E- Repro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPro-UK 35 mg
Trial: 38907935
Drug: Insulin efsitora
RxNorm normalized name: Insulin efsitora alfa
DrugBank: Insulin efsitora alfa (DB19013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin efsitora alfa (efsitora)
Trial: 38907935
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (glargine)
Trial: 38908841
Drug: ePRO intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ePRO intervention (responsive web application for weekly symptom reporting with proactive follow-up by nurses for 6 weeks)
Trial: 38909093
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy alongside usual care
Trial: 38909144
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg/day for approximately 80% of patients, 15 mg/day for the remaining patients)
Trial: 38909189
Drug: Tartarase dentifrice
RxNorm normalized name: tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartarase dentifrice (used twice daily)
Trial: 38909189
Drug: Tartarase dentifrice
RxNorm normalized name: tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartarase dentifrice (used with dental tray for 30 min, then brushed again once daily)
Trial: 38909671
Drug: Baseline follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline follicle-stimulating hormone levels
Trial: 38909740
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 25 mg weekly oral
Trial: 38909740
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily oral
Trial: 38909877
Drug: Tafamidis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis treatment
Trial: 38909998
Drug: ChitoCare gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChitoCare gel
Trial: 38910002
Drug: Vaginal application
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal application of Vagifem 30 µg once a day for 14 days prior to colposcopy
Trial: 38910002
Drug: Vaginal application
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal application of Vagifem 30 µg
Trial: 38911348
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nicotine cigarettes
Trial: 38911584
Drug: steroid/anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid/anesthetic
Trial: 38911647
Drug: Cancer treatment
RxNorm normalized name: Retinoids for cancer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer treatment in past 6 months
Trial: 38912296
Drug: Ustekinumab (UST)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (UST) therapy
Trial: 38912654
Drug: Tirzepatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (10 mg or 15 mg)
Trial: 38912692
Drug: Tailored aggressive
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored aggressive hydration (TAH) - 20 mL/kg bolus post-ERCP and 3 mL/kg/hr during and after ERCP
Trial: 38912692
Drug: Tailored standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored standard hydration (TSH) - 1.5 mL/kg/hr lactated Ringer's solution during and after ERCP
Trial: 38912884
Drug: 5% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% human albumin solution (HAS)
Trial: 38912905
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with high triglyceride to total cholesterol (TG/TC) ratio
Trial: 38913539
Drug: Lanreotide autogel/depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel/depot (120 mg every 28 days) plus best supportive care (BSC)
Trial: 38913574
Drug: Remdesivir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (200 mg on day 1; 100 mg daily up to day 5)
Trial: 38913710
Drug: VRC07-523LS IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS IV 2.5 mg/kg
Trial: 38913710
Drug: VRC07-523LS IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS IV 5 mg/kg
Trial: 38913710
Drug: VRC07-523LS IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS IV 20 mg/kg
Trial: 38913710
Drug: VRC07-523LS SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS SC 2.5 mg/kg
Trial: 38913710
Drug: VRC07-523LS SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS SC 5 mg/kg
Trial: 38913710
Drug: VRC07-523LS IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS IM 2.5 mg/kg
Trial: 38913881
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab plus chemotherapy (n=762)
Trial: 38913881
Drug: Neoadjuvant placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant placebo plus chemotherapy (n=383)
Trial: 38914016
Drug: 177 Lu-DOTATATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
Trial: 38914085
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (continue or terminate the thrombectomy procedure)
Trial: 38914270
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rivaroxaban twice daily plus 100 mg aspirin daily
Trial: 38914270
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rivaroxaban twice daily
Trial: 38914294
Drug: PDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (Q24W)
Trial: 38914294
Drug: Supplemental intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental intravitreal ranibizumab injections
Trial: 38914481
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) treatment with a 30% increase in intensity
Trial: 38914694
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g ENSO 16
Trial: 38914876
Drug: Trazo/Gaba 2.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazo/Gaba 2.5/25 mg t.i.d. for 8 weeks
Trial: 38914876
Drug: Trazo/Gaba 5/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazo/Gaba 5/50 mg t.i.d. for 8 weeks
Trial: 38914876
Drug: Trazo/Gaba 10/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazo/Gaba 10/100 mg t.i.d. for 8 weeks
Trial: 38914976
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride 10% spray (experimental group)
Trial: 38915038
Drug: Lever Positioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lever Positioning Manipulation (LPM) treatment, administered once every two days for a total of 12 times over 4 weeks.
Trial: 38915038
Drug: Sham LPM
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham LPM treatment, administered during the same period as Group 1.
Trial: 38915038
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (Group 3) without LPM treatment.
Trial: 38915065
Drug: TNFi (tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi (tumor necrosis factor inhibitor)
Trial: 38915106
Drug: Opioid taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid taper support program with PA intervention at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge.
Trial: 38915117
Drug: DynaFiT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DynaFiT therapy (bortezomib, lenalidomide, dexamethasone; daratumumab for frail patients)
Trial: 38915117
Drug: DynaFiT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DynaFiT therapy
Trial: 38915115
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg PO every other day
Trial: 38915115
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg PO twice daily
Trial: 38915115
Drug: Traditional blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional blood glucose lowering therapy + ramipril 10 mg PO
Trial: 38915423
Drug: Omigapil at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omigapil at daily doses ranging from 0.02 to 0.08 mg/kg for 12 weeks after a 4-week vehicle run-in.
Trial: 38915796
Drug: CTLA4-Ig and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA4-Ig and interleukin-2 (IL-2) therapy
Trial: 38915873
Drug: Perinatal antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perinatal antibiotics usage
Trial: 38916221
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - received oral/written information about the anaesthetic-surgical process and remained in a playroom waiting for surgery.
Trial: 38916223
Drug: Methylnaltrexone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone (0.15 mg/kg/d for 5 days)
Trial: 38916429
Drug: DNA-HIV-PT123 vaccine
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-HIV-PT123 vaccine with AS01B adjuvant
Trial: 38916429
Drug: DNA-HIV-PT123 vaccine
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-HIV-PT123 vaccine with MF59 adjuvant
Trial: 38916429
Drug: Low-dose protein/adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose protein/adjuvant with AS01B
Trial: 38916429
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120
Trial: 38916717
Drug: Vericiguat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (10 mg target dose)
Trial: 38916892
Drug: Subcutaneous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buprenorphine
Trial: 38917111
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (VDOT) for hydroxyurea
Trial: 38917404
Drug: Outpatient high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient high-dose methotrexate (HD-MTX) with glucarpidase 2000u
Trial: 38917525
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily plus mesalamine 1 g three times daily for 6 months
Trial: 38917525
Drug: Mesalamine 1
RxNorm normalized name: mesalamine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1 g three times daily for 6 months
Trial: 38918103
Drug: Ad26.COV2.S booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S booster (other dose levels)
Trial: 38918590
Drug: Topical simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical simvastatin
Trial: 38918590
Drug: Topical atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical atorvastatin
Trial: 38918780
Drug: TB/TBI treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB/TBI treatment
Trial: 38918869
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) techniques with 12 weeks of direct acting antiviral (DAA) treatment
Trial: 38919522
Drug: TP-based induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-based induction chemotherapy followed by radiotherapy (IC+RT)
Trial: 38919522
Drug: cisplatin-based concurrent
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin-based concurrent radiochemotherapy (CRT)
Trial: 38919826
Drug: Spartalizumab (PDR001)
RxNorm normalized name: Natalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Spartalizumab (PDR001) 300 mg intravenous every three weeks until disease progression or unacceptable toxicity
Trial: 38920407
Drug: Adavosertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle)
Trial: 38922435
Drug: Telerehabilitation home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telerehabilitation home program (TRP) in addition to pharmaceutical treatment
Trial: 38922435
Drug: Pharmaceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatment (Control)
Trial: 38922520
Drug: DKP/TRAM 25/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKP/TRAM 25/75 mg every 8 h (n=211)
Trial: 38922689
Drug: Twice Weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice Weekly Hemodialysis
Trial: 38922689
Drug: Thrice Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice Weekly Hemodialysis
Trial: 38922906
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day DHA supplementation during pregnancy (PGO-800)
Trial: 38922906
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day DHA supplementation during pregnancy (PGO-200)
Trial: 38922990
Drug: On demand
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On demand (OD) treatment with rFIXFc, n=22
Trial: 38923140
Drug: Evidence-based guideline-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based guideline-directed medical therapy (GDMT)
Trial: 38923140
Drug: Comorbidity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comorbidity treatment
Trial: 38923140
Drug: Sequence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence of treatment introduction and up-titration
Trial: 38923439
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin prophylaxis from <16 weeks until 36 weeks for high-risk women
Trial: 38923439
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin prophylaxis for high-risk women
Trial: 38923871
Drug: ABBV-599 high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg QD)
Trial: 38923871
Drug: Upadacitinib and
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib and ABBV-599 high dose
Trial: 38923910
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus chemotherapy (TIS+Chemo)
Trial: 38923965
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine administered twice daily with optical defocus (DIMS lenses)